We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
+71.93%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$766M
AUM Growth
+$254M
(+50%)
Cap. Flow
+$25.8M
Cap. Flow
% of AUM
3.37%
Top 10 Holdings %
Top 10 Hldgs %
55.55%
Holding
68
New
13
Increased
17
Reduced
11
Closed
9
Avg Time Held
4.2
quarters
Top 10 Avg Time Held
3.8
quarters
Top 20 Avg Time Held
4.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ocular Therapeutix
OCUL
|
+$7.81M |
| 2 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
+$7.36M |
| 3 |
FSDC
FS Development Corp. Class A Common Stock
FSDC
|
+$7.27M |
| 4 |
Cytokinetics
CYTK
|
+$6.84M |
| 5 |
Protagonist Therapeutics
PTGX
|
+$5.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Avenue Therapeutics, Inc. Common Stock
ATXI
|
+$10.7M |
| 2 |
APTO
Aptose Biosciences, Inc.
APTO
|
+$5.22M |
| 3 |
Fulcrum Therapeutics
FULC
|
+$4.11M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$3.76M |
| 5 |
MacroGenics
MGNX
|
+$3.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Ocular Therapeutix
OCUL
$1.59B
| $135M | 17.6% |
6,510,000
+525,800
| +9% | +$7.81M |
2019 Q1
7 quarters
|
|
2
Protara Therapeutics
TARA
$155M
| $61.9M | 8.09% |
2,558,472
| – | – |
2019 Q3
5 quarters
|
|
|
EIDX
3
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $41.5M | 5.42% |
315,550
| – | – |
2018 Q4
8 quarters
|
|
4
Eton Pharmaceutcials
ETON
$1.52B
| $32.8M | 4.29% |
4,040,000
+400,000
| +11% | +$3.09M |
2018 Q4
8 quarters
|
|
5
Codexis
CDXS
$145M
| $30.6M | 3.99% |
1,400,000
| – | – |
2014 Q1
27 quarters
|
|
6
Cardiff Oncology
CRDF
$78.6M
| $29.9M | 3.91% |
1,662,500
-69,100
| -4% | -$1.21M |
2020 Q2
2 quarters
|
|
|
TCON
7
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $29.5M | 3.85% |
125,919
+25,247
| +25% | +$3.51M |
2020 Q3
1 quarter
|
|
8
DELISTED
ChemoCentryx, Inc.
CCXI
| $21.7M | 2.83% |
350,000
-6,000
| -2% | -$344K |
2019 Q3
5 quarters
|
|
9
DELISTED
Acutus Medical Inc
AFIB
| $21.6M | 2.82% |
749,990
| – | – |
2020 Q3
1 quarter
|
|
10
Harrow
HROW
$1.06B
| $21M | 2.75% |
3,065,416
+106,416
| +4% | +$600K |
2018 Q3
9 quarters
|
|
11
TG Therapeutics
TGTX
$8.32B
| $20.2M | 2.63% |
387,500
-2,500
| -0.6% | -$84.5K |
2018 Q1
11 quarters
|
|
12
DELISTED
Xoma
XOMA
| $20.1M | 2.62% |
455,000
| – | – |
2017 Q1
15 quarters
|
|
13
Neurogene
NGNE
$431M
| $19.5M | 2.55% |
69,315
| – | – |
2019 Q3
5 quarters
|
|
14
DELISTED
Chimerix, Inc.
CMRX
| $19.1M | 2.5% |
3,956,500
+115,000
| +3% | +$417K |
2020 Q2
2 quarters
|
|
15
Celldex Therapeutics
CLDX
$2.22B
| $17.4M | 2.27% |
992,000
| – | – |
2020 Q2
2 quarters
|
|
16
Stereotaxis
STXS
$106M
| $15.4M | 2.01% |
3,021,436
| – | – |
2019 Q3
5 quarters
|
|
17
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $12.7M | 1.66% |
222,000
| – | – |
2018 Q1
11 quarters
|
|
18
Fortress Biotech
FBIO
$65M
| $12.3M | 1.61% |
259,167
+3,834
| +2% | +$166K |
2020 Q2
2 quarters
|
|
|
19
Cytokinetics
CYTK
$8.57B
| $12.1M | 1.58% |
582,800
+374,000
| +179% | +$6.84M |
2020 Q2
2 quarters
|
|
|
MYOV
20
DELISTED
Myovant Sciences Ltd.
MYOV
| $10.5M | 1.37% |
682,500
| – | – |
2020 Q1
3 quarters
|
|
21
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $10M | 1.31% |
281,287
+40,395
| +17% | +$697K |
2020 Q3
1 quarter
|
|
22
Seres Therapeutics
MCRB
$25.4M
| $9.8M | 1.28% |
16,766
| – | – |
2020 Q3
1 quarter
|
|
23
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $9.77M | 1.28% |
114,000
-350
| -0.3% | -$29.7K |
2020 Q2
2 quarters
|
|
24
DELISTED
KalVista Pharmaceuticals
KALV
| $8.93M | 1.17% |
470,203
| – | – |
2020 Q1
3 quarters
|
|
25
Vaxcyte
PCVX
$10.4B
| $8.91M | 1.16% |
335,200
+22,200
| +7% | +$825K |
2020 Q3
1 quarter
|
|
Similar funds
CFO
PFM
HBCM
HAS
AI
TPA
ZDA
NW
Opaleye Management's Q4 2020 Portfolio in Review
As of Q4 2020, Opaleye Management held 68 positions worth $766M, up 50% from $511M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Opaleye Management deployed $25.8M of net new capital in Q4 2020, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was Tricida, Inc. Common Stock: 959,000 shares worth $6.76M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Aptose Biosciences, Inc., an estimated $5.22M trimmed.
- Opaleye Management's largest Q4 2020 buy was Tricida, Inc. Common Stock: 959,000 shares worth $6.76M.
- Opaleye Management added most to Ocular Therapeutix in Q4 2020, an estimated $7.81M increase.
- Opaleye Management's biggest Q4 2020 reduction was Aptose Biosciences, Inc., cutting an estimated $5.22M.
- Opaleye Management fully exited Avenue Therapeutics, Inc. Common Stock in Q4 2020, selling an estimated $10.7M.
- Opaleye Management's ten largest holdings make up 56% of its $766M portfolio in Q4 2020.
- Opaleye Management opened 13 new positions and closed 9 in Q4 2020.
- Opaleye Management's portfolio value rose 50% quarter-over-quarter to $766M.
Based on Opaleye Management's 13F filing for Q4 2020, filed 12 Feb 2021.